Premium
RHabdomyosarcoma: Response with chemotherapy prior to radiation in patients with gross residual disease
Author(s) -
Tefft Melvin,
Fernandez Carlos H.,
Moon Thomas E.
Publication year - 1977
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(197702)39:2<665::aid-cncr2820390244>3.0.co;2-b
Subject(s) - medicine , regimen , chemotherapy , radiation therapy , rhabdomyosarcoma , complete response , chemotherapy regimen , surgery , oncology , sarcoma , pathology
One hundred and ten Group III patients enrolled in the IRS Study have been reviewed. Of these, 39 are fully and 56 are partially evaluable. Combining the data for both groups, 77/95 (81%) have shown complete or partial response/no measurable disease and this has been maintained in 53/95 (56%). No patient received premature RT for local progression during the time of pre‐radiation chemotherapy. However, 15/95 patients have shown local recurrence or direct extension to neighboring tissues; 13/15 could be reviewed. Only 3/13 have recurred at a time related to the delay in starting radiation. Overall survival for Group III patients is 72%‐85% (Regimen F and Regimen E respectively).